SAVED
File name .JPG
File alt. text
Image should be px wide x px tall.
Select Image
home - Pancreas - Pancreatic Cancers - Mucinous Cystadenoma Written by Dr Sebastian Zeki
Knowledge


Knows the presentation investigation and staging of pancreatic
cancer

Recognises the importance of considering and being able to identify
uncommon pancreatic tumours (such as neuroendocrine or
intrapapillary mucinous tuours)

Knows the range of potential therapies and recognises the factors
that make such tumours potentially operable or inoperable

Knows the prevalence and natural history of benign cysts/serous
cystadenoma and potentially malignant cystic lesions

Knows the options for palliative treatment
Skills
Shows ability to sequence investigations appropriately
Understands value of multi-disciplinary team
Recognises the importance of considering possibility that the tumour
is unusual

Behaviours
Communicates effectively within the multi-disciplinary team and with
the patient and their family

Mucinous Cystadenoma

Mucinous cystadenoma Mucin Mucin Mucin Macrocystic spaces lined by mucous-secreting cellsVery cellular collagenous and sometimes calcified stromal layer beneath epithelium with oestrogen/progesterone staining spindle cells EpidemiologyThey have a Malignant/ potential to be malignant.Middle aged woman are the most common patients.It is the Most common of the cystic neoplasms.Macrocystic spaces produce mucin within a mass is characteristic.It is Murderously difficult to make diagnosis from biopsy (cells often denuded).It is located in body or tail. Classification:-MCN with low-grade dysplasia.-MCN with moderate dysplasia.-MCN with high-grade dysplasia (which can be in situ or invasive- (17% of HGD and behaves as ductal adenocarcinoma). Categories are based on the degree of epithelial dysplasia. Written by Dr Sebastian Zeki

Related Stories

•Deep learning-based CT model for non-invasive prediction of tertiary lymphoid structures in pancreatic cancer: a multicenter study with prospective validation in an immunochemotherapy cohort

•Lack of tumor-derived LCN2 sensitizes pancreatic cancer cells to ferroptosis induction

•Unveiling the Diagnostic Value and Potential Therapeutic Targets of Phenylalanine Metabolism in Pancreatic Cancer via Integrated Multi-Omics and Machine Learning

•Comprehensive Clinicopathologic, Immunohistochemical, and Genomic Profiling of Sporadic Ampullary Somatostatin-producing D-cell Neuroendocrine Tumors Identifies Recurrent HRAS Hotspot Mutations

•Overcoming cancer resistance in pancreatic cancer: toward dynamic precision oncology